Dr Micheal Looney Consultant Anaesthetist Connolly Hospital Blanchardstown. To Delay or Not to Delay Hip Fracture Surgery

Similar documents
Dr Ben Edwards Consultant Anaesthetist Sheffield Teaching Hospitals

Consensus Statement for Management of Anticoagulants and Antiplatelet drugs in Patients with Hip Fracture

The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center

DOAC and NOAC are terms for a novel class of directly acting oral anticoagulant drugs including Rivaroxaban, Apixaban, Edoxaban, and Dabigatran.

Preventing Stroke in Patients with Atrial Fibrillation: USING THE EVIDENCE

Challenging Anticoagulation Case Studies. Earl J. Hope, M.D. Tower Health Cardiology

Anticoagulation Task Force

ANTICOAGULANTS AND HIP FRACTURE SURGERY. Jon Antrobus Anaesthetist Borders General Hospital

KCS Congress: Impact through collaboration

Guidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban

Bleeding Management Strategies. Aiming for the best Outcomes August 27, Amit Gupta, MD FACC FSCAI Interventional Cardiologist CANM

Prostate Biopsy Alerts

Asif Serajian DO FACC FSCAI

GWTG Post-Discharge Follow-up Form

The Role of Oral Anticoagulants in Atrial Fibrillation: What You Need to Know Now. Bradley A. Hardin, MD Richard F.

The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center

Anticoagulation Management Around Endoscopy: GI Perspective. Nathan Landesman, DO FACOI Flint Gastroenterology Associates October 11, 2017

Appendix 2H - SECONDARY CARE CONVERSION GUIDELINES ORAL ANTICOAGULANTS

Individual Therapeutic Selection Of Anti-coagulants And Periprocedural. Miguel Valderrábano, MD

What s new with DOACs? Defining place in therapy for edoxaban &

HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised

Clinical Practice Guideline for Anticoagulation Management

Novel Anticoagulants: Emerging Evidence

Managing Perioperative Anticoagulation. Edie Shen MD

Comparison of novel oral anticoagulants (NOACs)

Update on Oral Anticoagulants. Dr. Miten R. Patel Cancer Specialists of North Florida Cell

Oral Anticoagulation Drug Class Prior Authorization Protocol

Professional Practice Minutes December 7, 2016

Is Apixaban Effective for the Prevention of Stroke in Patients With Non-Valvular Atrial Fibrillation?

Afib, Stroke, and DOAC. Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS

NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS

Anaesthesia. Clinical overview articles. Update in. Neck of femur fracture: perioperative management. Ronald Cheung

Post-procedure dose ok after hours. 12 hours (q 24h dosing only) assuming surgical hemostasis; second dose 24 hours after first dose.

New Oral Anticoagulants

Atrial fibrillation and anticoagulation JIR-PING BOEY, DEPARTMENT OF HAEMATOLOGY, FLINDERS MEDICAL CENTRE FEBRUARY 2016

Under Triage and Anticoagulants in the Geriatric Trauma Population Fragile Must be Italian. Barry McKenzie, MD St. Vincent Healthcare

Intrinsic + Common = aptt. Extrinsic + Common = PT. Common Pathway

ADVOCATE HEALTHCARE GUIDELINE FOR ANTITHROMBOTIC REVERSAL

Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism

Adult Reversal of Anticoagulation and Anti-platelet Agents for Life- Threatening Bleeding or Emergency Surgery Protocol

Atrial fibrillation: current approaches to management

New Age Anticoagulants: Bleeding Considerations

Oral Anticoagulants Update. Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation

Holy Crap! Why is a Cardiologist Speaking at a GI Meeting? Jonathan A. Rapp, MD, FACC, FSCAI Cardiologist, Mercy Heart Institute Cincinnati, OH

Appendix IV - Prescribing Guidance for Apixaban

Analysing Apixaban: Potential Growth Driver for Pfizer and Bristol Myers Squibb. Tro Kalayjian Chief Medical Analyst Chimera Research Group

New Anticoagulants Therapies

Treatment Options and How They Work

Anticoagulation Overview Jed Delmore, MD, FACS, FACOG Professor Obstetrics and Gynecology University of Kansas School of Medicine, Wichita

Disclosures. Overview. Have you ever. The Perioperative Management of Anticoagulants. No financial conflicts of interest to disclose

Dr Calum Young Cardiologist Tauranga

Venothromboembolism prophylaxis: Trauma and Orthopaedics Clinical guideline, V2

Antiplatelets and Anticoagulants. Helen Leung, PharmD PGY1 Pharmacy Resident Memorial Hermann-Texas Medical Center

Direct Oral Anticoagulants An Update

Clinical issues which drug for which patient

Coagulation, Haemostasis and interpretation of Coagulation tests

Atrial Fibrillation Version 2 11/4/15 This order set must be used with an admission order set if patient not already admitted.

Atrial Fibrillation. A guide for Southwark General Practice. Key Messages. Always work within your knowledge and competency

Edoxaban. Direct Xa inhibitor Direct thrombin inhibitor Direct Xa inhibitor Direct Xa inhibitor

Updates in Atrial Fibrillation

Advances in Anticoagulation

Reducing the Use of Reversal Agents in a Community Hospital

Atrial Fibrillation Implementation challenges. Lesley Edgar Ross Maconachie

Tim Brown, PharmD, BCACP, FASHP Director of Clinical Pharmacotherapy, Akron General Medical Center for Family Medicine Professor, Northeast Ohio

Management of haemorrhage in patients taking DOACs/ NOACs (direct/ novel oral anticoagulants) Guideline. Contents

PRACTICAL MANAGEMENT OF NOAC s December 8,

Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute

Update on the NOAC s: 2018 Daniel Blanchard, MD, FACC, FAHA

Atrial Fibrillation is Common. The (S)Low-down on Rapid Afib Resuscitation Step ED Dx - Rx 4/4/2017. There Are 5 Causes of Atrial Fibrillation

PREOPERATIVE PATIENT PREPARATION PROTOCOL

Appendix C Factors to consider when choosing between anticoagulant options and FAQs

Multidisciplinary Geriatric Trauma Care Guideline

Outpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2015

Xarelto (rivaroxaban) Prescriber Guide

Reversal Agents for Anticoagulants Understanding the Options. Katisha Vance, MD, FACP Alabama Oncology January 28, 2017

INR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA

CARDIOLOGY. Certification Updates with Clinical Aspects. Federal Aviation Administration

NOACS/DOACS*: COAGULATION TESTS

Challenges in Coagulation

Haematology Subcommittee of PTAC Meeting held 16 March 2016

Cost and Prevalence of A fib. Atrial Fibrillation: Guideline Directed Treatment. Prevalence of A Fib. Risk Factors for A Fib. Risk Factors for A Fib

Anticoagulants: Agents, Pharmacology and Reversal

Management of Novel Oral Anticoagulants (NOACs) with the DAWN AC modules

PULMONARY EMBOLISM (PE): DIAGNOSIS AND TREATMENT

Aims. AF and Stroke risk Guidance re anticoagulation Novel oral anticoagulants (NOACs) in non-valvular AF (NVAF) Practical Issues Patient Case Studies

These are guidelines only and can be deviated from if it is thought to be in the patient s best interest.

New Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY

a. A pharmacist may order a baseline SCr per protocol

Role and impact of orthogeriatric service in the hip fracture care pathway: 15-year experience

Nibal R. Chamoun, Pharm.D., BCPS Clinical Assistant Professor of Pharmacy Practice at the Lebanese American University Clinical Pharmacy Coordinator

Emergency Management of Patients on Direct Oral Anticoagulants (DOACs)

Patient Encounters in the Primary Care Setting

ADMINISTRATIVE CLINICAL Page 1 of 6

10 Key Things the Vascular Community Should Know about the DOACs Heather Gornik, MD, RVT, RPVI

Nanik Hatsakorzian Pharm.D/MPH

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization

Reversal of Direct Oral Anticoagulants. Why are we now seeing so many patients on DOACs? Objectives. DOAC: Recurrent VTE. DOAC: Intracranial Bleeding

Heart Valves: Before and after surgery

EACTS Adult Cardiac Database

Bios 6648: Design & conduct of clinical research

Transcription:

Dr Micheal Looney Consultant Anaesthetist Connolly Hospital Blanchardstown To Delay or Not to Delay Hip Fracture Surgery

"You may delay, but time will not, and lost time is never found again." Benjamin Franklin

Reasons for Delay > 48 Hours

ASA Classification of Patients

Acceptable Reasons for Delay

Acceptable Reasons for Delay

Anaemia

Anaemia ~ 40% patients have anaemia Hb conc decreases 2.5g/dL perioperative period Adhere to a restrictive transfusion strategy Consider transfusion if Hb 8 g/dl or less Transfuse if symptomatic of anaemia or if patient has stable cardiovascular disease

Severe Electrolyte Imbalance

Severe Electrolyte Imbalance Hyponatraemia why should we treat it preoperatively? Increase in subsequent peri-operative complications Hypernatraemia assoc with increased mortality after surgery

Uncontrolled Diabetes

Uncontrolled Diabetes Patients who manifested a serum glucose greater than 220 mg/dl (12 mmol/l) had a 25% infection rate including: wound infections pneumonia urinary tract infections bacteraemia or severe sepsis Perioperative glucose levels greater than 220 mg/dl (12mmol/L) increased the likelihood of infection by a factor of seven in orthopaedic trauma patients even with no known history of DM

Uncontrolled / Acute Left Ventricular Failure An echocardiogram is indicated for anyone with: suspicious systolic murmur, dyspnoea of unknown cause worsening CCF If echo is delayed, surgery should proceed with relevant anaesthetic precautions and monitoring in place Bedside echocardiography may be useful tool to stratify surgical risk and optimize patients by assessing a patient s: intravascular volume status myocardial contractility/ventricular ejection fraction valvular heart disease in the peri-operative period Aortic Stenosis - echocardiography is indicated if it has not been performed recently

Correctable Cardiac Arrhythmia, Ventricular Rhythm > 120bpm

Correctable Cardiac Arrhythmia, Ventricular Rhythm > 120bpm Normal atrial activity accounts 10% ventricular filling up to 40% fast ventricular heart rates Elderly more dependent atrial activity due reduced elasticity ventricles Adverse effects AF more profound elderly and those underlying cardiovascular disease

Correctable Cardiac Arrhythmia, Ventricular Rhythm > 120bpm

Chest Infection With Sepsis

Chest Infection and Sepsis Prevalence preoperative pneumonia 1.2% Independent risk factor mortality and adverse events Underweight BMI assoc w higher mortality within 30 days Time from admission to surgery not assoc adverse events

Reversible Coagulopathy Drug Class Drug Name SAB Surgery Anti-platelet Clopidogrel (Plavix) Not recommended within 7 days of taking last dose of 75mg/day of clopidogrel. Low Molecular Weight Heparin Enoxaparin (Clexane) Avoid SAB if prophylactic dose administered within the last 12 hours. 1 & 4 Avoid SAB if therapeutic dose administered within the previous 24 hours. 1 & 4 Note these intervals are extended in renal impairment. If surgery is required within 48 hours of last dose it is suggested that platelets (2 pools) be ordered and in the hospital prior to surgery Unfractionated Heparin Heparin infusion Cease infusion 4 hours before surgery

Reversible Coagulopathy Drug Class Drug Name SAB Surgery Coumadins Warfarin INR should be 1.3 prior to placement of SAB Direct Thrombin Inhibitors Dabigatran (Pradaxa) 2 4 days after last dose depending on creatinine clearance INR normally takes 5 days to return to normal after cessation of warfarin. INR < 2. If surgery is required before this, emergency reversal of warfarin can be performed. 2 4 days after last dose depending on creatinine clearance * Can reverse with idarucizumab Factor Xa Inhibitors Rivaroxaban (Xarelto) Avoid SAB for three days after last dose taken Proceed with Sx 48 hours after last dose taken Apixaban (Eliquis) Avoid SAB for three days after last dose taken Proceed with Sx 48 hours after last dose of taken

Conclusions Delays due to medical optimisation of patients could be improved AAGBI clear guidelines on appropriate delays surgery NOACs problematic cause delays until cost effective antidotes